论文部分内容阅读
目的 :探讨替尼泊苷联合方案治疗交叉表达淋系和髓系抗原急性白血病的化疗疗效。方法 :应用替尼泊苷联合阿糖胞苷、环磷酰胺、长春地辛及泼尼松组成 TA或 TA+COP方案 ,治疗伴淋系抗原表达的急性髓细胞白血病 (L y+ AML) 2 4例和伴髓系抗原表达的急性淋巴细胞白血病(My+ AL L) 1 7例。结果 :完全缓解 (CR)率为 5 6 .1 % (2 3/ 4 1 ) ,总有效率为 80 .5 % (33/ 4 1 )。与常规方案 (DA、VDL P)诱导疗效相比有显著性差异 (P<0 .0 1 )。其中 L y+ AML 的 CR率为 5 8.3% ,总有效率为 79.2 % ;My+ AL L 的 CR率为 5 2 .9% ,总有效率为 82 .4 %。复治性 L y+ AML / My+ AL L 总有效率为 72 .7% (8/ 1 1 )。两种方案的骨髓抑制明显 ,毒副作用能够耐受。结论 :L y+ AML 和 My+ AL L不宜采用常规诱导缓解方案 ,TA和 TACOP方案宜作为此类患者的首选治疗方案
Objective: To investigate the effect of chemotherapy with teniposide in the treatment of cross-lymphoid and myeloid leukemia. Methods: The combination of teniposide and cytarabine, cyclophosphamide, vindesine and prednisone was used in the treatment of acute myeloid leukemia (LY + AML) 24 Cases and acute myeloid leukemia (My + AL L) with 17 cases of myeloid antigen expression. Results: The complete remission (CR) rate was 56.1% (2 3/4 1) and the total effective rate was 80.5% (33/4 1). There was a significant difference (P <0.01) between the curative effect and the conventional regimen (DA, VDL P). The CR rate of L y + AML was 53.3% and the total effective rate was 79.2%. The CR rate of My + AL L was 52.2% and the total effective rate was 82.4%. The total effective rate of retreatment L y + AML / My + AL L was 72.7% (8/1 1). Bone marrow suppression of the two options is obvious, toxic and side effects can be tolerated. Conclusion: L y + AML and My + AL L should not be used conventional induction remission program, TA and TACOP program should be as the preferred treatment of such patients